An article titled “The Hows and Whys of the Skin Biopsy Test For Parkinson’s Disease” was published last week on Medscape, a leading online resource for medical news and expert perspectives.
The story covers the discovery of Lewy bodies (made primarily of alpha-synuclein) in 1912 and what we’ve learned about them since, as well as the challenges that clinicians face today in diagnosing Parkinson’s disease.
“This type of testing shifts the paradigm. It really changes how we approach, counsel, and treat patients,” says Stuart Isaacson, MD, director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, and a consultant for CND Life Sciences.
CND’s Chief Medical Officer and Co-Founder, Dr. Todd Levine, outlines how the Syn-One Test is performed, the ways it can impact the lives of patients, and how it might contribute to the development of disease-modifying therapies for Parkinson’s and related disorders.